Worldwide Uterine Cancer Therapeutics & Diagnostics Industry to 2027 - Increasing Advancements in Cancer Screening and Treatment Methods Presents Opportunities

DUBLIN, March 1, 2022 /PRNewswire/ -- The "Uterine Cancer Therapeutics & Diagnostics Market Research Report by Cancer Type, by Product, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Uterine Cancer Therapeutics & Diagnostics Market size was estimated at USD 18.95 billion in 2020, is expected to reach USD 20.04 billion in 2021, and is projected to grow at a CAGR of 6.13% to reach USD 28.75 billion by 2027.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2027 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Uterine Cancer Therapeutics & Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

• Based on Cancer Type, the market was studied across Adenosquamous Carcinoma, Endometrial Adenocarcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma.
• Based on Product, the market was studied across Diagnostics and Therapeutics. The Diagnostics is further studied across Biopsy, CT Scan, Dilation and Curettage, Hysteroscopy, and Pelvic Ultrasound. The Therapeutics is further studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Surgery.
• Based on Region, the market was studied across the Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Uterine Cancer Therapeutics & Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Uterine Cancer Therapeutics & Diagnostics Market, including Abbott Laboratories, AbbVie Inc, Ability Pharma, Allergan, Inc., Apotex Inc., ARIAD Pharmaceuticals, Inc, AstraZeneca, Becton Dickinson and Company, BioMerieux SA, Danaher Corporation, Elekta AB (pub), Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC., Johnson & Johnson Services, Inc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Uterine Cancer Therapeutics & Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Uterine Cancer Therapeutics & Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Uterine Cancer Therapeutics & Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Uterine Cancer Therapeutics & Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Uterine Cancer Therapeutics & Diagnostics Market?
6. What is the market share of the leading vendors in the Global Uterine Cancer Therapeutics & Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Uterine Cancer Therapeutics & Diagnostics Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing awareness of uterine cancer in physicians and healthcare providers
5.1.1.2. Rising in importance of the women health
5.1.1.3. Increasing healthcare expenditure and rising focus of government on providing adequate healthcare solutions
5.1.2. Restraints
5.1.2.1. Expensive treatment methods along with adverse side effects and severe toxicity of the medications
5.1.3. Opportunities
5.1.3.1. Increasing advancements in the cancer screening and treatment methods
5.1.3.2. Developing countries organising various programmes about uterine cancer severity and importance
5.1.4. Challenges
5.1.4.1. Low success rate of cancer drug clinical trials
5.2. Cumulative Impact of COVID-19

6. Uterine Cancer Therapeutics & Diagnostics Market, by Cancer Type
6.1. Introduction
6.2. Adenosquamous Carcinoma
6.3. Endometrial Adenocarcinoma
6.4. Papillary Serous Carcinoma
6.5. Uterine Sarcoma

7. Uterine Cancer Therapeutics & Diagnostics Market, by Product
7.1. Introduction
7.2. Diagnostics
7.2.1. Biopsy
7.2.2. CT Scan
7.2.3. Dilation and Curettage
7.2.4. Hysteroscopy
7.2.5. Pelvic Ultrasound
7.3. Therapeutics
7.3.1. Chemotherapy
7.3.2. Immunotherapy
7.3.3. Radiation Therapy
7.3.4. Surgery

8. Americas Uterine Cancer Therapeutics & Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand

10. Europe, Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Abbott Laboratories
12.2. AbbVie Inc
12.3. Ability Pharma
12.4. Allergan, Inc.
12.5. Apotex Inc.
12.6. ARIAD Pharmaceuticals, Inc
12.7. AstraZeneca
12.8. Becton Dickinson and Company
12.9. BioMerieux SA
12.10. Danaher Corporation
12.11. Elekta AB (pub)
12.12. Eli Lilly and Company
12.13. F. Hoffmann-La Roche AG
12.14. GlaxoSmithKline PLC.
12.15. Johnson & Johnson Services, Inc
12.16. Merck & Co., Inc.
12.17. Novartis AG
12.18. Pfizer Inc.
12.19. Sanofi S.A.
12.20. Siemens Healthineers AG
12.21. Takeda Pharmaceutical Company Limited
12.22. Teva Pharmaceutical Industries Ltd.

13. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/hzce5z

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets